{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T20:41:56Z","timestamp":1768855316097,"version":"3.49.0"},"reference-count":131,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite a decrease in disease severity since the emergence of the severe acute respiratory syndrome coronavirus 2 Omicron variant, coronavirus disease-2019 (COVID-19) continues to pose a significant threat to patients with haematological malignancies (HM). Although repeated booster vaccinations enhance protection against severe illnesses in immunocompromised individuals, they remain at heightened risk of adverse outcomes. This underscores the crucial need for effective pharmacologic strategies to prevent and treat infection. This review examines current strategies for preventing severe COVID-19 in patients with HM, focusing on pre-exposure prophylaxis and early treatment of COVID-19. New monoclonal antibodies have been developed, offering effective pre-exposure prophylaxis. Antiviral agents and monoclonal antibodies demonstrated efficacy in limiting severe COVID-19 outcomes in patients with HM, though some patients, particularly the elderly, remain at risk of critical illness and death. Prolonged infection over months is also common, particularly in patients with lymphoid malignancies. Sustained viral shedding and ongoing mutation may be associated with chronic symptoms and is the likely source of several novel variants of concern that prolonged the pandemic. While HM subtype and advanced age are risk factors for severe or persistent COVID-19, there are no accurate tools for predicting individual risk. Given this uncertainty, prompt medical consultation, timely prescription of antiviral agents, and close monitoring are essential to minimize the risk of adverse outcomes in this vulnerable population.<\/jats:p>","DOI":"10.1093\/jac\/dkaf489","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:03:16Z","timestamp":1765976596000},"source":"Crossref","is-referenced-by-count":0,"title":["Strategies for mitigating severe COVID-19 in patients with haematological malignancy during the omicron era"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5050-3349","authenticated-orcid":false,"given":"Keiji","family":"Okinaka","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, National Cancer Center Hospital East , Chiba ,","place":["Japan"]},{"name":"Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2598-1621","authenticated-orcid":false,"given":"Joshua T","family":"Schiffer","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center , Seattle, WA ,","place":["USA"]},{"name":"Clinical Research Division, Fred Hutchinson Cancer Center , Seattle, WA ,","place":["USA"]},{"name":"Department of Medicine, University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"2026011902093587900_dkaf489-B1","doi-asserted-by":"publisher","first-page":"102553","DOI":"10.1016\/j.eclinm.2024.102553","article-title":"Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022","volume":"71","author":"Salmanton-Garcia","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026011902093587900_dkaf489-B2","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41467-023-44276-x","article-title":"Risk of COVID-19 death in adults who received booster COVID-19 vaccinations in England","volume":"15","author":"Ward","year":"2024","journal-title":"Nat Commun"},{"key":"2026011902093587900_dkaf489-B3","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s15010-023-02169-7","article-title":"Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey","volume":"52","author":"Lahmer","year":"2024","journal-title":"Infection"},{"key":"2026011902093587900_dkaf489-B4","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/ejh.14108","article-title":"Mortality and clinical outcomes following SARS-CoV-2 infection among individuals with haematological malignancies: a Danish population-based cohort study","volume":"111","author":"Lund","year":"2023","journal-title":"Eur J Haematol"},{"key":"2026011902093587900_dkaf489-B5","doi-asserted-by":"publisher","first-page":"100747","DOI":"10.1016\/j.lanepe.2023.100747","article-title":"Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study","volume":"35","author":"Evans","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2026011902093587900_dkaf489-B6","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/jamaoncol.2023.3066","article-title":"Deaths due to COVID-19 in patients with cancer during different waves of the pandemic in the US","volume":"9","author":"Potter","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026011902093587900_dkaf489-B7","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(24)00107-4","article-title":"Changes in hospital mortality in patients with cancer during the COVID-19 pandemic (ISARIC-CCP-UK): a prospective, multicentre cohort study","volume":"25","author":"Turtle","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026011902093587900_dkaf489-B8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ijid.2023.10.013","article-title":"Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings","volume":"137","author":"Rossi","year":"2023","journal-title":"Int J Infect Dis"},{"key":"2026011902093587900_dkaf489-B9","doi-asserted-by":"publisher","first-page":"5400","DOI":"10.3390\/jcm13185400","article-title":"Outcomes and patterns of evolution of patients with hematological malignancies during the COVID-19 pandemic: a nationwide study (2020\u20132022)","volume":"13","author":"Garcia-Carretero","year":"2024","journal-title":"J Clin Med"},{"key":"2026011902093587900_dkaf489-B10","doi-asserted-by":"publisher","first-page":"106110","DOI":"10.1016\/j.jinf.2024.01.009","article-title":"Disparities in COVID-19 mortality amongst the immunosuppressed: a systematic review and meta-analysis for enhanced disease surveillance","volume":"88","author":"Leston","year":"2024","journal-title":"J Infect"},{"key":"2026011902093587900_dkaf489-B11","doi-asserted-by":"publisher","first-page":"1408969","DOI":"10.3389\/fimmu.2024.1408969","article-title":"Risk factors for COVID-19 pneumonia in patients with hematological malignancies: a multi-center, prospective study in China","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"2026011902093587900_dkaf489-B12","doi-asserted-by":"publisher","first-page":"1389345","DOI":"10.3389\/fonc.2024.1389345","article-title":"Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy","volume":"14","author":"Pinana","year":"2024","journal-title":"Front Oncol"},{"key":"2026011902093587900_dkaf489-B13","doi-asserted-by":"publisher","first-page":"1506366","DOI":"10.3389\/fonc.2024.1506366","article-title":"Prevalence and risk factors for long COVID among cancer patients: a systematic review and meta-analysis","volume":"14","author":"Xu","year":"2024","journal-title":"Front Oncol"},{"key":"2026011902093587900_dkaf489-B14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1470-2045(23)00056-6","article-title":"SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry","volume":"24","author":"Cortellini","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026011902093587900_dkaf489-B15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.annepidem.2025.02.004","article-title":"Higher prevalence of long COVID observed in cancer survivors: insights from a US nationwide survey","volume":"103","author":"Wang","year":"2025","journal-title":"Ann Epidemiol"},{"key":"2026011902093587900_dkaf489-B16","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1007\/s11136-024-03726-9","article-title":"Long-term effects of the COVID-19 pandemic for patients with cancer","volume":"33","author":"Debie","year":"2024","journal-title":"Qual Life Res"},{"key":"2026011902093587900_dkaf489-B17","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/S1470-2045(21)00573-8","article-title":"Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study","volume":"22","author":"Pinato","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026011902093587900_dkaf489-B18","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.cmi.2025.05.032","article-title":"Management of COVID-19 in immunocompromised patients: an European Society of Clinical Microbiology and Infectious Diseases consensus document","volume":"31","author":"Bartoletti","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"2026011902093587900_dkaf489-B19","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1038\/s41375-025-02649-9","article-title":"Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-10)","volume":"39","author":"Cesaro","year":"2025","journal-title":"Leukemia"},{"key":"2026011902093587900_dkaf489-B20","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1182\/blood-2016-01-634873","article-title":"How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation","volume":"127","author":"Waghmare","year":"2016","journal-title":"Blood"},{"key":"2026011902093587900_dkaf489-B21","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.idc.2019.02.004","article-title":"Respiratory virus infections of the stem cell transplant recipient and the hematologic malignancy patient","volume":"33","author":"Fontana","year":"2019","journal-title":"Infect Dis Clin North Am"},{"key":"2026011902093587900_dkaf489-B22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejca.2021.12.011","article-title":"Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: should humoral responses be monitored? A position article","volume":"162","author":"Barriere","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026011902093587900_dkaf489-B23","doi-asserted-by":"publisher","first-page":"105577","DOI":"10.1016\/j.ebiom.2025.105577","article-title":"Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses","volume":"113","author":"Ciabattini","year":"2025","journal-title":"EBioMedicine"},{"key":"2026011902093587900_dkaf489-B24","doi-asserted-by":"publisher","first-page":"e2211132120","DOI":"10.1073\/pnas.2211132120","article-title":"Mechanistic model for booster doses effectiveness in healthy, cancer, and immunosuppressed patients infected with SARS-CoV-2","volume":"120","author":"Voutouri","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026011902093587900_dkaf489-B25","doi-asserted-by":"publisher","first-page":"126547","DOI":"10.1016\/j.vaccine.2024.126547","article-title":"Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer","volume":"46","author":"Body","year":"2025","journal-title":"Vaccine"},{"key":"2026011902093587900_dkaf489-B26","doi-asserted-by":"publisher","first-page":"105385","DOI":"10.1016\/j.ebiom.2024.105385","article-title":"Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID","volume":"109","author":"Chen","year":"2024","journal-title":"EBioMedicine"},{"key":"2026011902093587900_dkaf489-B27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41408-023-00940-5","article-title":"Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia","volume":"14","author":"Roberts","year":"2024","journal-title":"Blood Cancer J"},{"key":"2026011902093587900_dkaf489-B28","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/bjh.19126","article-title":"Immunogenicity and clinical effectiveness of mRNA vaccine booster against SARS-CoV-2 Omicron in patients with haematological malignancies: a national prospective cohort study","volume":"204","author":"Kevlicius","year":"2024","journal-title":"Br J Haematol"},{"key":"2026011902093587900_dkaf489-B29","doi-asserted-by":"publisher","first-page":"E312","DOI":"10.1002\/ajh.26626","article-title":"Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: an EPICOVIDEHA survey report","volume":"97","author":"Blennow","year":"2022","journal-title":"Am J Hematol"},{"key":"2026011902093587900_dkaf489-B30","doi-asserted-by":"publisher","first-page":"e2400034","DOI":"10.1200\/OA-24-00034","article-title":"Differential survival among patients with cancer by COVID-19 vaccination status: an analysis of the ASCO COVID-19 registry","volume":"1","author":"Kirkwood","year":"2024","journal-title":"JCO Oncol Adv"},{"key":"2026011902093587900_dkaf489-B31","doi-asserted-by":"publisher","first-page":"e240288","DOI":"10.1001\/jamanetworkopen.2024.0288","article-title":"Severe COVID-19 in vaccinated adults with hematologic cancers in the Veterans Health Administration","volume":"7","author":"Anand","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026011902093587900_dkaf489-B32","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.3324\/haematol.2023.283015","article-title":"Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients","volume":"108","author":"Laracy","year":"2023","journal-title":"Haematologica"},{"key":"2026011902093587900_dkaf489-B33","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jinf.2023.06.024","article-title":"Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant variants","volume":"87","author":"Kamboj","year":"2023","journal-title":"J Infect"},{"key":"2026011902093587900_dkaf489-B34","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S1473-3099(24)00804-1","article-title":"Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial","volume":"25","author":"Haidar","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026011902093587900_dkaf489-B35","doi-asserted-by":"publisher","first-page":"ofad314","DOI":"10.1093\/ofid\/ofad314","article-title":"Prevention of COVID-19 following a single intramuscular administration of adintrevimab: results from a phase 2\/3 randomized, double-blind, placebo-controlled trial (EVADE)","volume":"10","author":"Ison","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026011902093587900_dkaf489-B36","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1093\/cid\/ciaf265","article-title":"Safety and efficacy of pemivibart, a long-acting monoclonal antibody, for prevention of symptomatic COVID-19: interim results from a phase 3 randomized clinical trial (CANOPY)","volume":"81","author":"Wolfe","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026011902093587900_dkaf489-B37","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf424","article-title":"Clinical practice guideline update by the Infectious Diseases Society of America on the treatment and management of COVID-19: pemivibart for pre-exposure prophylaxis, vilobelimab for critical illness, and abatacept or infliximab for severe or critical illness","author":"Bhimraj","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026011902093587900_dkaf489-B38","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s12185-023-03663-2","article-title":"Pre-exposure prophylaxis with tixagevimab\/cilgavimab for coronavirus disease 2019 (COVID-19) during the Omicron BA.5 wave at a single institution in Japan","volume":"118","author":"Kawashima","year":"2023","journal-title":"Int J Hematol"},{"key":"2026011902093587900_dkaf489-B39","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00277-023-05572-0","article-title":"Effectiveness of tixagevimab\/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study","volume":"103","author":"Demel","year":"2024","journal-title":"Ann Hematol"},{"key":"2026011902093587900_dkaf489-B40","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1182\/blood.2022018283","article-title":"Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies","volume":"141","author":"Davis","year":"2023","journal-title":"Blood"},{"key":"2026011902093587900_dkaf489-B41","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1007\/s00277-024-05671-6","article-title":"Efficacy and safety of tixagevimab\/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies","volume":"103","author":"Reimann","year":"2024","journal-title":"Ann Hematol"},{"key":"2026011902093587900_dkaf489-B42","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40121-024-01089-9","article-title":"Preventing severe COVID-19 with tixagevimab-cilgavimab in hematological patients treated with anti-CD20 monoclonal antibodies: an international multicenter study","volume":"14","author":"Azuly","year":"2025","journal-title":"Infect Dis Ther"},{"key":"2026011902093587900_dkaf489-B43","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1111\/bjh.19321","article-title":"Evaluating tixagevimab\/cilgavimab prophylaxis in allogeneic haematopoietic cell transplantation recipients for COVID-19 prevention","volume":"204","author":"Trepl","year":"2024","journal-title":"Br J Haematol"},{"key":"2026011902093587900_dkaf489-B44","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1056\/NEJMc2119407","article-title":"Efficacy of antibodies and antiviral drugs against COVID-19 Omicron variant","volume":"386","author":"Takashita","year":"2022","journal-title":"N Engl J Med"},{"key":"2026011902093587900_dkaf489-B45","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2","volume":"602","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"2026011902093587900_dkaf489-B46","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1038\/s41598-022-08559-5","article-title":"In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate","volume":"12","author":"Touret","year":"2022","journal-title":"Sci Rep"},{"key":"2026011902093587900_dkaf489-B47","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/j.cell.2022.05.014","article-title":"Potent cross-reactive antibodies following Omicron breakthrough in vaccinees","volume":"185","author":"Nutalai","year":"2022","journal-title":"Cell"},{"key":"2026011902093587900_dkaf489-B48","doi-asserted-by":"publisher","first-page":"eado2817","DOI":"10.1126\/scitranslmed.ado2817","article-title":"AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults","volume":"16","author":"Cai","year":"2024","journal-title":"Sci Transl Med"},{"key":"2026011902093587900_dkaf489-B49","doi-asserted-by":"publisher","first-page":"938","DOI":"10.15585\/mmwr.mm7342a1","article-title":"Genomic surveillance for SARS-CoV-2 variants: circulation of Omicron XBB and JN.1 lineages\u2014United States, May 2023-September 2024","volume":"73","author":"Ma","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026011902093587900_dkaf489-B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20411\/pai.v10i1.752","article-title":"Escape of SARS-CoV-2 variants KP.1.1, LB.1, and KP3.3 from approved monoclonal antibodies","volume":"10","author":"Planas","year":"2024","journal-title":"Pathog Immun"},{"key":"2026011902093587900_dkaf489-B51","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMc2404555","article-title":"Immunobridging for pemivibart, a monoclonal antibody for prevention of COVID-19","volume":"391","author":"Schmidt","year":"2024","journal-title":"N Engl J Med"},{"key":"2026011902093587900_dkaf489-B52","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S1473-3099(24)00812-0","article-title":"Sipavibart: when a success changes into a failure","volume":"25","author":"Focosi","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026011902093587900_dkaf489-B53","author":"NCCN Clinical Practice Guidelines in Oncology Prevention and Treatment of Cancer-Related Infections Version 1.2025"},{"key":"2026011902093587900_dkaf489-B54","author":"IDSA Guidelines on the Treatment and Management of Patients with COVID-19"},{"key":"2026011902093587900_dkaf489-B55","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"2026011902093587900_dkaf489-B56","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe COVID-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N Engl J Med"},{"key":"2026011902093587900_dkaf489-B57","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"key":"2026011902093587900_dkaf489-B58","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial","volume":"401","author":"Butler","year":"2023","journal-title":"Lancet"},{"key":"2026011902093587900_dkaf489-B59","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1056\/NEJMoa2309003","article-title":"Nirmatrelvir for vaccinated or unvaccinated adult outpatients with COVID-19","volume":"390","author":"Hammond","year":"2024","journal-title":"N Engl J Med"},{"key":"2026011902093587900_dkaf489-B60","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1093\/infdis\/jiad275","article-title":"Clinical antiviral efficacy of remdesivir in coronavirus disease 2019: an open-label, randomized controlled adaptive platform trial (PLATCOV)","volume":"228","author":"Jittamala","year":"2023","journal-title":"J Infect Dis"},{"key":"2026011902093587900_dkaf489-B61","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S1473-3099(23)00493-0","article-title":"Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial","volume":"24","author":"Schilling","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026011902093587900_dkaf489-B62","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1093\/cid\/ciae308","article-title":"How immunocompromised hosts were left behind in the quest to control the COVID-19 pandemic","volume":"79","author":"Boeckh","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026011902093587900_dkaf489-B63","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1093\/jac\/dkac256","article-title":"Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge","volume":"77","author":"Piccicacco","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026011902093587900_dkaf489-B64","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1186\/s12879-024-09708-z","article-title":"Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1\/BQ.1.1\/XBB.1.5","volume":"24","author":"Molina","year":"2024","journal-title":"BMC Infect Dis"},{"key":"2026011902093587900_dkaf489-B65","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/ajt.17199","article-title":"Short-course early outpatient remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the omicron BA.2 wave","volume":"23","author":"Solera","year":"2023","journal-title":"Am J Transplant"},{"key":"2026011902093587900_dkaf489-B66","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1093\/cid\/ciad460","article-title":"Remdesivir reduced mortality in immunocompromised patients hospitalized for COVID-19 across variant waves: findings from routine clinical practice","volume":"77","author":"Mozaffari","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026011902093587900_dkaf489-B67","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S2213-2600(22)00528-8","article-title":"Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials","volume":"11","author":"Amstutz","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026011902093587900_dkaf489-B68","doi-asserted-by":"publisher","first-page":"S137","DOI":"10.1093\/cid\/ciae512","article-title":"Management of vulnerable patients hospitalized for COVID-19 with remdesivir: a retrospective comparative effectiveness study of mortality in US hospitals","volume":"79","author":"Mozaffari","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026011902093587900_dkaf489-B69","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.1093\/cid\/ciae511","article-title":"Remdesivir effectiveness in reducing the risk of 30-day readmission in vulnerable patients hospitalized for COVID-19: a retrospective US cohort study using propensity scores","volume":"79","author":"Mozaffari","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026011902093587900_dkaf489-B70","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.3390\/life14101252","article-title":"The effectiveness and safety of remdesivir use in COVID-19 patients with neutropenia: a retrospective cohort study","volume":"14","author":"Liu","year":"2024","journal-title":"Life (Basel)"},{"key":"2026011902093587900_dkaf489-B71","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1093\/cid\/ciae510","article-title":"Remdesivir-associated survival outcomes among immunocompromised patients hospitalized for COVID-19: real-world evidence from the Omicron-dominant era","volume":"79","author":"Mozaffari","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026011902093587900_dkaf489-B72","doi-asserted-by":"publisher","first-page":"e235044","DOI":"10.1001\/jamahealthforum.2023.5044","article-title":"Clinical risk and outpatient therapy utilization for COVID-19 in the medicare population","volume":"5","author":"Wilcock","year":"2024","journal-title":"JAMA Health Forum"},{"key":"2026011902093587900_dkaf489-B73","doi-asserted-by":"publisher","first-page":"e2336678","DOI":"10.1001\/jamanetworkopen.2023.36678","article-title":"Nirmatrelvir-ritonavir and COVID-19 mortality and hospitalization among patients with vulnerability to COVID-19 complications","volume":"6","author":"Dormuth","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026011902093587900_dkaf489-B74","doi-asserted-by":"publisher","first-page":"101939","DOI":"10.1016\/j.eclinm.2023.101939","article-title":"Nirmatrelvir\/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry","volume":"58","author":"Salmanton-Garcia","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026011902093587900_dkaf489-B75","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1093\/cid\/ciad400","article-title":"Oral nirmatrelvir and ritonavir for coronavirus disease 2019 in vaccinated, nonhospitalized adults aged 18\u201350 years","volume":"77","author":"Faust","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026011902093587900_dkaf489-B76","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1111\/bjh.20039","article-title":"Effectiveness of nirmatrelvir\/ritonavir in hospitalized haematological malignancy patients with mild-to-moderate COVID-19: a retrospective study","volume":"206","author":"Yu","year":"2025","journal-title":"Br J Haematol"},{"key":"2026011902093587900_dkaf489-B77","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S1473-3099(23)00118-4","article-title":"Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system","volume":"23","author":"Lewnard","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026011902093587900_dkaf489-B78","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s15010-024-02255-4","article-title":"Real-world application of nirmatrelvir\/ritonavir in hospitalized COVID-19 patients with onset of symptoms beyond 5 days: a comparative study","volume":"52","author":"Luo","year":"2024","journal-title":"Infection"},{"key":"2026011902093587900_dkaf489-B79","doi-asserted-by":"publisher","first-page":"5478","DOI":"10.1038\/s41467-024-49458-9","article-title":"A unifying model to explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic efficacy","volume":"15","author":"Esmaeili","year":"2024","journal-title":"Nat Commun"},{"key":"2026011902093587900_dkaf489-B80","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/S1473-3099(25)00221-X","article-title":"Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial","volume":"25","author":"Weinstein","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026011902093587900_dkaf489-B81","doi-asserted-by":"publisher","first-page":"e70377","DOI":"10.1002\/jmv.70377","article-title":"Clinical characteristics and treatment efficacy in patients with SARS-CoV-2 positivity after nirmatrelvir-ritonavir therapy","volume":"97","author":"Yang","year":"2025","journal-title":"J Med Virol"},{"key":"2026011902093587900_dkaf489-B82","doi-asserted-by":"publisher","first-page":"e192052","DOI":"10.1172\/JCI192052","article-title":"Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2","volume":"135","author":"Esmaeili","year":"2025","journal-title":"J Clin Invest"},{"key":"2026011902093587900_dkaf489-B83","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-023-06649-6","article-title":"A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes","volume":"623","author":"Sanderson","year":"2023","journal-title":"Nature"},{"key":"2026011902093587900_dkaf489-B84","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.cmi.2024.06.018","article-title":"Effectiveness and safety of molnupiravir in the intended-use population: an observational cohort study","volume":"30","author":"Abu Ahmad","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026011902093587900_dkaf489-B85","doi-asserted-by":"publisher","first-page":"106952","DOI":"10.1016\/j.ijantimicag.2023.106952","article-title":"Molnupiravir compared to nirmatrelvir\/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry","volume":"62","author":"Salmanton-Garcia","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026011902093587900_dkaf489-B86","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/bjh.18895","article-title":"Oral anti-viral therapy for early COVID-19 infection in patients with haematological malignancies: a multicentre prospective cohort","volume":"202","author":"Minoia","year":"2023","journal-title":"Br J Haematol"},{"key":"2026011902093587900_dkaf489-B87","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3390\/cancers16051055","article-title":"Comparing molnupiravir to nirmatrelvir\/ritonavir (paxlovid) in the treatment of mild-to-moderate COVID-19 in immunocompromised cancer patients","volume":"16","author":"Haddad","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026011902093587900_dkaf489-B88","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.7326\/M23-1636","article-title":"Outpatient treatment of confirmed COVID-19: living, rapid practice points from the American College of Physicians (version 2)","volume":"176","author":"Qaseem","year":"2023","journal-title":"Ann Intern Med"},{"key":"2026011902093587900_dkaf489-B89","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1182\/blood.2022017257","article-title":"Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey","volume":"140","author":"Pagano","year":"2022","journal-title":"Blood"},{"key":"2026011902093587900_dkaf489-B90","doi-asserted-by":"publisher","first-page":"107095","DOI":"10.1016\/j.ijantimicag.2024.107095","article-title":"Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy vs. monotherapy for high-risk immunocompromised patients with mild-to-moderate SARS-CoV2 infection during the Omicron era: a prospective cohort study","volume":"63","author":"Calderon-Parra","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"2026011902093587900_dkaf489-B91","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3390\/pathogens14030216","article-title":"Efficacy and safety of sotrovimab versus oral antiviral for early treatment in high-risk patients in Omicron era: a multicenter retrospective study","volume":"14","author":"Russo","year":"2025","journal-title":"Pathogens"},{"key":"2026011902093587900_dkaf489-B92","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41533-024-00374-x","article-title":"Real-world severe COVID-19 outcomes associated with use of antivirals and neutralising monoclonal antibodies in Scotland","volume":"34","author":"Tibble","year":"2024","journal-title":"NPJ Prim Care Respir Med"},{"key":"2026011902093587900_dkaf489-B93","doi-asserted-by":"publisher","first-page":"e002238","DOI":"10.1136\/bmjresp-2023-002238","article-title":"Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk COVID-19 patients in north west London: a retrospective cohort study","volume":"11","author":"Drysdale","year":"2024","journal-title":"BMJ Open Respir Res"},{"key":"2026011902093587900_dkaf489-B94","doi-asserted-by":"publisher","first-page":"e1262","DOI":"10.1002\/iid3.1262","article-title":"Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID-19: a systematic review and meta-analysis","volume":"12","author":"Amani","year":"2024","journal-title":"Immun Inflamm Dis"},{"key":"2026011902093587900_dkaf489-B95","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1038\/s41467-022-31615-7","article-title":"Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains","volume":"13","author":"Case","year":"2022","journal-title":"Nat Commun"},{"key":"2026011902093587900_dkaf489-B96","doi-asserted-by":"publisher","first-page":"2400252","DOI":"10.2807\/1560-7917.ES.2025.30.10.2400252","article-title":"Impact of SARS-CoV-2 variant mutations on susceptibility to monoclonal antibodies and antiviral drugs: a non-systematic review, April 2022 to October 2024","volume":"30","author":"Vukovikj","year":"2025","journal-title":"Euro Surveill"},{"key":"2026011902093587900_dkaf489-B97","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/S1473-3099(24)00353-0","article-title":"Comparative effectiveness of combination therapy with nirmatrelvir-ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir-ritonavir in patients hospitalised with COVID-19: a target trial emulation study","volume":"24","author":"Choi","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026011902093587900_dkaf489-B98","doi-asserted-by":"publisher","first-page":"eadk1599","DOI":"10.1126\/scitranslmed.adk1599","article-title":"SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency","volume":"16","author":"Li","year":"2024","journal-title":"Sci Transl Med"},{"key":"2026011902093587900_dkaf489-B99","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/bjh.19143","article-title":"Prolonged shedding of viable SARS-CoV-2 in immunocompromised patients with haematological malignancies: a prospective study","volume":"204","author":"Ichikawa","year":"2024","journal-title":"Br J Haematol"},{"key":"2026011902093587900_dkaf489-B100","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s15010-023-02125-5","article-title":"Early combination therapy of COVID-19 in high-risk patients","volume":"52","author":"Orth","year":"2024","journal-title":"Infection"},{"key":"2026011902093587900_dkaf489-B101","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3324\/haematol.2021.280407","article-title":"Prolonged viral replication in patients with hematologic malignancies hospitalized with COVID-19","volume":"107","author":"Garcia-Vidal","year":"2022","journal-title":"Haematologica"},{"key":"2026011902093587900_dkaf489-B102","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1016\/S2666-5247(23)00336-1","article-title":"SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis","volume":"5","author":"Raglow","year":"2024","journal-title":"Lancet Microbe"},{"key":"2026011902093587900_dkaf489-B103","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41408-023-00897-5","article-title":"Clinical and immunological characteristics of prolonged SARS-CoV-2 Omicron infection in hematologic disease","volume":"13","author":"Ikeda","year":"2023","journal-title":"Blood Cancer J"},{"key":"2026011902093587900_dkaf489-B104","doi-asserted-by":"publisher","first-page":"ofad612","DOI":"10.1093\/ofid\/ofad612","article-title":"A multinational case series describing successful treatment of persistent severe acute respiratory syndrome coronavirus 2 infection caused by Omicron sublineages with prolonged courses of nirmatrelvir\/ritonavir","volume":"11","author":"Snell","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026011902093587900_dkaf489-B105","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/cid\/ciad181","article-title":"Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients","volume":"77","author":"Mikulska","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026011902093587900_dkaf489-B106","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s40001-024-02062-5","article-title":"Does early combination vs. Monotherapy improve clinical outcomes of clinically extremely vulnerable patients with COVID-19? Results from a retrospective propensity-weighted analysis","volume":"29","author":"Maria","year":"2024","journal-title":"Eur J Med Res"},{"key":"2026011902093587900_dkaf489-B107","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/jac\/dkad105","article-title":"Current outcomes of SARS-CoV-2 Omicron variant infection in high-risk haematological patients treated early with antivirals","volume":"78","author":"Aiello","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026011902093587900_dkaf489-B108","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/jac\/dkae482","article-title":"Efficacy and safety of antiviral therapies for the treatment of persistent COVID-19 in immunocompromised patients since the Omicron surge: a systematic review","volume":"80","author":"Hirsch","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026011902093587900_dkaf489-B109","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1056\/NEJMsb2104756","article-title":"SARS-CoV-2 variants in patients with immunosuppression","volume":"385","author":"Corey","year":"2021","journal-title":"N Engl J Med"},{"key":"2026011902093587900_dkaf489-B110","doi-asserted-by":"publisher","first-page":"e0078025","DOI":"10.1128\/jvi.00780-25","article-title":"Intra-host SARS-CoV-2 diversity in immunocompromised people living with HIV provides insight into the evolutionary trajectory of SARS-CoV-2","volume":"99","author":"Joseph","year":"2025","journal-title":"J Virol"},{"key":"2026011902093587900_dkaf489-B111","doi-asserted-by":"publisher","first-page":"7999","DOI":"10.1038\/s41467-024-51924-3","article-title":"Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections","volume":"15","author":"Nooruzzaman","year":"2024","journal-title":"Nat Commun"},{"key":"2026011902093587900_dkaf489-B112","doi-asserted-by":"publisher","first-page":"pgaf085","DOI":"10.1093\/pnasnexus\/pgaf085","article-title":"Clinical and molecular landscape of prolonged SARS-CoV-2 infection with resistance to remdesivir in immunocompromised patients","volume":"4","author":"Iriyama","year":"2025","journal-title":"PNAS Nexus"},{"key":"2026011902093587900_dkaf489-B113","doi-asserted-by":"publisher","first-page":"105819","DOI":"10.1016\/j.ebiom.2025.105819","article-title":"Integrated virologic analysis of resistance to nirmatrelvir\/ritonavir in individuals across four phase 2\/3 clinical studies for the treatment of COVID-19","volume":"118","author":"Baniecki","year":"2025","journal-title":"EBioMedicine"},{"key":"2026011902093587900_dkaf489-B114","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1093\/cid\/ciac601","article-title":"Sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the severe acute respiratory syndrome coronavirus 2 omicron variant","volume":"76","author":"Huygens","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026011902093587900_dkaf489-B115","doi-asserted-by":"publisher","first-page":"e2435431","DOI":"10.1001\/jamanetworkopen.2024.35431","article-title":"Emerging SARS-CoV-2 resistance after antiviral treatment","volume":"7","author":"Tamura","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026011902093587900_dkaf489-B116","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1038\/s41467-024-45641-0","article-title":"Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients","volume":"15","author":"Standing","year":"2024","journal-title":"Nat Commun"},{"key":"2026011902093587900_dkaf489-B117","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00520-025-09333-9","article-title":"When to resume antitumor therapy in COVID-19-infected tumor patients: a retrospective, real-world study","volume":"33","author":"Pan","year":"2025","journal-title":"Support Care Cancer"},{"key":"2026011902093587900_dkaf489-B118","doi-asserted-by":"publisher","first-page":"ofad306","DOI":"10.1093\/ofid\/ofad306","article-title":"Successful treatment of persistent symptomatic coronavirus disease 19 infection with extended-duration nirmatrelvir-ritonavir among outpatients with hematologic cancer","volume":"10","author":"Liu","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026011902093587900_dkaf489-B119","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jtct.2022.09.002","article-title":"Revised guidelines for coronavirus disease 19 management in hematopoietic cell transplantation and cellular therapy recipients (August 2022)","volume":"28","author":"Dioverti","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2026011902093587900_dkaf489-B120","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best practice considerations by the American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2026011902093587900_dkaf489-B121","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/cid\/ciae116","article-title":"Outcomes in hematopoietic cell transplant and chimeric antigen receptor T-cell therapy recipients with pre-cellular therapy SARS-CoV-2 infection","volume":"79","author":"Nimgaonkar","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026011902093587900_dkaf489-B122","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s00277-024-05653-8","article-title":"Clinical characteristics and outcomes of allogeneic hematopoietic stem cell transplantation recipients with coronavirus disease 2019 caused by the Omicron variant: a prospective, observational cohort study","volume":"103","author":"Fan","year":"2024","journal-title":"Ann Hematol"},{"key":"2026011902093587900_dkaf489-B123","doi-asserted-by":"publisher","first-page":"ofae038","DOI":"10.1093\/ofid\/ofae038","article-title":"Characteristics of coronavirus disease in allogeneic hematopoietic stem cell transplantation during the omicron wave: a single-center study","volume":"11","author":"Zhu","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026011902093587900_dkaf489-B124","doi-asserted-by":"publisher","first-page":"e2354991","DOI":"10.1001\/jamanetworkopen.2023.54991","article-title":"Efficacy and safety of 5-day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial","volume":"7","author":"Yotsuyanagi","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026011902093587900_dkaf489-B125","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s40121-024-01010-4","article-title":"Real-world effectiveness of ensitrelvir in reducing severe outcomes in outpatients at high risk for COVID-19","volume":"13","author":"Takazono","year":"2024","journal-title":"Infect Dis Ther"},{"key":"2026011902093587900_dkaf489-B126","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/cid\/ciae529","article-title":"Virologic response and safety of ibuzatrelvir, a novel SARS-CoV-2 antiviral, in adults with COVID-19","volume":"80","author":"Mortezavi","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026011902093587900_dkaf489-B127","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa2301425","article-title":"Oral simnotrelvir for adult patients with mild-to-moderate COVID-19","volume":"390","author":"Cao","year":"2024","journal-title":"N Engl J Med"},{"key":"2026011902093587900_dkaf489-B128","doi-asserted-by":"publisher","first-page":"106339","DOI":"10.1016\/j.jinf.2024.106339","article-title":"Real-world effectiveness and safety of simnotrelvir\/ritonavir for COVID-19: a nationwide, multicenter, prospective, observational cohort study in China","volume":"89","author":"Han","year":"2024","journal-title":"J Infect"},{"key":"2026011902093587900_dkaf489-B129","doi-asserted-by":"publisher","first-page":"102359","DOI":"10.1016\/j.eclinm.2023.102359","article-title":"Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial","volume":"67","author":"Zhan","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026011902093587900_dkaf489-B130","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1473-3099(23)00577-7","article-title":"Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study","volume":"24","author":"Fan","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026011902093587900_dkaf489-B131","doi-asserted-by":"publisher","first-page":"e0155624","DOI":"10.1128\/aac.01556-24","article-title":"Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrier","volume":"69","author":"Zhao","year":"2025","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkaf489\/66444097\/dkaf489.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkaf489\/66444097\/dkaf489.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:09:43Z","timestamp":1768806583000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf489\/8429089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":131,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,19]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf489","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,19]]},"article-number":"dkaf489"}}